MATTHEW BRAMS: Open Payments
NPI 1639187263 · HOUSTON, TX. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$249,262 in 236 payments from 13 companies in 2025. Trend: 2023 $246,648 · 2024 $264,631 · 2025 $249,262
Speaker / faculty: $221,038Travel & lodging: $17,511Food & beverage: $5,576Consulting: $5,137
| Company | Payments | Amount |
|---|---|---|
| Otsuka America Pharmaceutical, Inc. | 77 | $93,191 |
| Vanda Pharmaceuticals Inc. | 84 | $82,691 |
| Teva Pharmaceuticals USA, Inc. | 28 | $43,334 |
| E.R. Squibb & Sons, L.L.C. | 31 | $29,171 |
| Janssen Pharmaceuticals, Inc | 2 | $235 |
| Tris Pharma Inc | 3 | $201 |
| Axsome Therapeutics, Inc. | 2 | $162 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | 1 | $71 |
| Alkermes, Inc. | 2 | $53 |
| ABBVIE INC. | 2 | $53 |
Products named: FANAPT, ABILIFY MAINTENA, REXULTI, AUSTEDO XR, COBENFY, UZEDY, ABILIFY ASIMTUFII, SPRAVATO.
Industry payments across TX — which companies pay providers there.
